Phase I Study of Combination of Capecitabine and Erlotinib Concurrent With Radiotherapy in Patients With Non-Operable Locally Advanced Pancreatic Cancer

NCT00565487 Phase 1 COMPLETED

The primary purpose of this study is to determine the best dosage of Capecitabine and Tarceva combination in the setting of radiation and to assess treatment effectiveness, progression-free survival and overall survival.

Details

Lead sponsor	Milton S. Hershey Medical Center
Phase	Phase 1
Status	COMPLETED
Enrolment	15
Start date	2007-12
Completion	2014-08-05

Conditions

• Pancreatic Cancer

Interventions

• Capecitabine, Tarceva

Primary outcomes

• To determine optimal dosage for Capecitabine and Tarceva combination in the setting of radiation. — Two years

Countries

United States